Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma
10.3969/j.issn.1008-794X.2024.09.022
- VernacularTitle:经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展
- Author:
Yanji ZHANG
1
;
Huiyuan WANG
;
Hao LI
;
Xuhua DUAN
Author Information
1. 450052 河南郑州 郑州大学临床医学院
- Keywords:
hepatocellular carcinoma;
transcatheter arterial chemoembolization;
hepatic arterial perfusion chemotherapy
- From:
Journal of Interventional Radiology
2024;33(9):1039-1044
- CountryChina
- Language:Chinese
-
Abstract:
Primary hepatocellular carcinoma(HCC)is a common malignant tumor in the world,and in China it is the fourth most common malignant tumor and the second cause of cancer mortality.In China,most HCC patients are already in the advanced stage when the clinical diagnosis of HCC is confirmed,and it is impossible to adopt a radical treatment for the patient.At present,transarterial chemoembolization(TACE)has become the mainstream therapeutic option for unresectable HCC,and hepatic arterial perfusion chemotherapy(HAIC),as a new therapeutic option,has attracted extensive attention.This article reviews the research progress in TACE combined with HAIC for the treatment of HCC,and obtains the following conclusions:TACE combined with HAIC has better efficacy than TACE along in patients with unresectable HCC of BCLC stage C,massive HCC,and portal venous invasion,but there is no significant difference in the therapeutic efficacy between TACE combined with HAIC and TACE alone for patients with HCC of BCLC stage A/B.It is expected that this review will provide effective recommendations for treating HCC patients in clinical practice,further standardize TACE treatment and later-stage HAIC treatment,and provide the basis for the design of relevant clinical studies.
